United Therapeutics Corporation (UTHR)
Last Price$361.1(1.7%)
Market Cap$16.1B
LTM EPS
$24.3
+15.5% YOY growth
NTM EPS
$29.7
+22.0% YOY growth
Current P/E
14.5x LTM
10.8x NTM
52w high P/E
16.5x LTM
12.7x NTM
52w low P/E
10.2x LTM
8.3x NTM
10Y avg P/E
9.3x LTM
6.5x NTM
UTHR Peter Lynch Chart
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Explore more intrinsic value tools hub for UTHR
Earnings growth model
Peter Lynch Fair Value
Earnings Power Value
Discount rate
Ben Graham Fair Value
Reverse DCF
Relative Value
Intrinsic Value
DCF value calculator
Margin of safety
FAQ
What is United Therapeutics Corporation earnings per share (EPS)?
United Therapeutics Corporation earnings per share (EPS) for the twelve months ending Feb 21, 2025 was $24.3, a 15.5% increase year-over-year.
What is United Therapeutics Corporation Price to Earnings (P/E) ratio?
As of Feb 21, 2025, United Therapeutics Corporation's P/E ratio is 14.5x. This is calculated by dividing the current share price of $361.1 by the Earnings per Share (EPS) for the trailing twelve months, which is $24.3. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
Is United Therapeutics Corporation overvalued or undervalued?
United Therapeutics Corporation is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $406.0, compared to a market price of around $361.1. This suggests a potential undervaluation of 12.4%.